Biogen Inc. (BIIB)

337.35
0.07 0.02
NASDAQ : Health Technology
Prev Close 337.42
Open 335.05
Day Low/High 333.66 / 340.70
52 Wk Low/High 249.17 / 388.67
Volume 542.14K
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 201.48M
Market Cap 67.98B
EPS 11.90
P/E Ratio 21.84
Div & Yield N.A. (N.A)
Venator Materials, Biogen Idec, Corning: 'Mad Money' Lightning Round

Venator Materials, Biogen Idec, Corning: 'Mad Money' Lightning Round

Jim Cramer is bullish on Venator Materials, Biogen Idec, Corning.

Good Stocks on Sale: Cramer's 'Mad Money' Recap (Wednesday 10/25/17)

Good Stocks on Sale: Cramer's 'Mad Money' Recap (Wednesday 10/25/17)

Jim Cramer has a special set of rules for what to buy and where to take a pass.

Biogen Announces AFFINITY Phase 2 Trial Initiation For Opicinumab (Anti-LINGO-1) In Multiple Sclerosis

Biogen Announces AFFINITY Phase 2 Trial Initiation For Opicinumab (Anti-LINGO-1) In Multiple Sclerosis

Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis...

Closing Bell: Stocks Surge on Strong Earnings Reports Across the Board

Closing Bell: Stocks Surge on Strong Earnings Reports Across the Board

Stocks closed confidently higher Tuesday.

Biogen Shares Hit After Poor U.S. Sales for Muscular Atrophy Treatment

Biogen Shares Hit After Poor U.S. Sales for Muscular Atrophy Treatment

During the third quarter, U.S. sales of Biogen's spinal muscular atrophy treatment Spinraza totaled $198M, compared with consensus of $212M.

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Powerhouse performances from Caterpillar and 3M inspire a Dow rally, leading the index to new all-time highs in its 54th record close of the year.

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Better-than-expected earnings from a number of key Dow components sweep markets higher.

Caterpillar, McDonald's and 3M Earnings Fuel Stock Rebound

Caterpillar, McDonald's and 3M Earnings Fuel Stock Rebound

Strong earnings from Dow components Caterpillar, McDonald's and 3M were on track to push the blue-chip index higher after a 0.23% decline on Monday.

McDonald's, Sears and Amazon - 5 Things You Must Know Before the Market Opens

McDonald's, Sears and Amazon - 5 Things You Must Know Before the Market Opens

U.S. stock futures are rising on Tuesday, after Wall Street's record-breaking streak came to an end during the previous trading session.

Biogen Reports Quarterly Revenues Of $3.1 Billion

Biogen Reports Quarterly Revenues Of $3.1 Billion

Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2017 financial results, including: Total revenues of $3.

Biogen Increases Profit Potential On Investigational Alzheimer's Disease Treatment Aducanumab Through Amended Agreement With Neurimmune Holding AG

Biogen Increases Profit Potential On Investigational Alzheimer's Disease Treatment Aducanumab Through Amended Agreement With Neurimmune Holding AG

Biogen (NASDAQ: BIIB) announced today that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer's disease, by reducing the potential royalty payment on potential...

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

A decision should be made 'in the coming days.'

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

A string of severe hurricanes that swept across the south and southeastern portions of the U.S. and Puerto Rico toward the end of the third quarter could put a big dent in economic growth.

Biogen Confirms Commitment To Tackle Multiple Sclerosis Through Comprehensive Approach

Biogen Confirms Commitment To Tackle Multiple Sclerosis Through Comprehensive Approach

Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle multiple sclerosis (MS) at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment...

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

Healthcare Drives Small Gains for Dow While Rest of Market Slips

Healthcare Drives Small Gains for Dow While Rest of Market Slips

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

Earnings beats from UnitedHealth Group Inc. and Johnson & Johnson led the healthcare sector to recover from a days-long presidential beating.

A Stock Market Pullback Is Imminent and These 28 Stocks Will Help You Survive It

A Stock Market Pullback Is Imminent and These 28 Stocks Will Help You Survive It

Fundstrat has the key calls for seven top sectors.

Biogen Shoots for More Upside

Biogen Shoots for More Upside

We like this name for higher prices into year-end.

Chart of the Day: Biogen

We like this name for higher prices into year-end.

Celgene Is Not a Sell, Jim Cramer Rebuts Analysts' Call

Celgene Is Not a Sell, Jim Cramer Rebuts Analysts' Call

Morgan Stanley analysts downgraded shares of Celgene over concerns of generic drug pressures. Those concerns are not warranted just yet and Celgene is not a sell, Jim Cramer reasoned.

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

Biogen's SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead To Improved Motor Function Across A Broad Population Of People Living With Spinal Muscular Atrophy

Biogen's SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead To Improved Motor Function Across A Broad Population Of People Living With Spinal Muscular Atrophy

Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA ® (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy...

The Small Caps May Be Trying to Warn Us About Something

I will be watching Friday's small underperformance in the small caps.

Biogen To Report Third Quarter 2017 Financial Results On October 24, 2017

Biogen To Report Third Quarter 2017 Financial Results On October 24, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2017 financial results on Tuesday, October 24, 2017, before the financial markets open.

Biogen Appoints Camille Lee As SVP, Alzheimer's Disease Therapeutic Area

Biogen Appoints Camille Lee As SVP, Alzheimer's Disease Therapeutic Area

Biogen (NASDAQ: BIIB) announced the appointment of Camille Lee as Senior Vice President, Alzheimer's Therapeutic Area, effective today.

Biogen Appoints Sanjay Jariwala As SVP, Worldwide Medical

Biogen Appoints Sanjay Jariwala As SVP, Worldwide Medical

Biogen (NASDAQ: BIIB) announced today the appointment of Dr.

Biogen To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Biogen To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley 15 th Annual Global Healthcare Conference.

TheStreet Quant Rating: B+ (Buy)